Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial

Coudert, Bruno; Asselain, Bernard; Campone, Mario; Spielmann, M.; Machiels, Jean‐Pascal; Penault‐Llorca, Frédérique; Serin, Daniel; Lévy, Christelle; Romieu, Gilles; Canon, Jean-Luc; Orfeuvre, Hubert; Piot, G.; Petit, Thierry; Jérusalem, Guy; Audhuy, B.; Veyret, Corinne; Beauduin, M.; Eymard, Jean‐Christophe; Martin, Anne‐Laure; Roché, Henri; Breast Group, UNICANCER

doi:10.1634/theoncologist.2011-0442

Public

Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial

Published in The Oncologist • May 18, 2012

Authors:

Bruno Coudert

Bernard Asselain

Mario Campone

Abstract

PURPOSE: The initial report from the Programme Action Concertée Sein (PACS) PACS01 trial demonstrated a benefit at 5 years for disease-free survival (DFS) and overall survival (OS) rates with the sequential administration of docetaxel after FEC100 (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), a...

Subject

Medicine

Docetaxel

Epirubicin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!